The U.K. drugmaker originally recalled the product at the consumer level in December after finding “small visible particulate matters of a gelatinous/oily nature that appear black” in some lots of the drug. Hikma didn’t disclose what the particulate matter was.
The drugmaker said March 4 it is now expanding the recall to medical facilities and retailers.
Ketorolac tromethamine is an anti-inflammatory drug used to manage pain.
Hikma said using the recalled drug could result in the particulate matter going into patients’ lungs and cause acute respiratory distress.
The drugmaker said it hasn’t received any reports of adverse events related to the recalled drug.
Read the full news release here.
More articles on pharmacy:
Mount Carmel to pay $477K after pharmacists cited in fatal patient overdoses
Express Scripts, 6 others receive PBM excellence awards
Public Citizen slams the FDA for not identifying drug in coronavirus-related shortage
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.